Katie J Doores
Overview
Explore the profile of Katie J Doores including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
7843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oluka G, Sembera J, Katende J, Ankunda V, Kato L, Kurshan A, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006690
This study assessed the long-term dynamics of neutralizing antibodies in a Ugandan cohort primarily exposed to the A.23.1 SARS-CoV-2 variant, examining how this shaped immune breadth and potency against diverse...
2.
Pickering S, Wilson H, Bravo E, Perera M, Seow J, Graham C, et al.
Nat Commun
. 2024 Dec;
15(1):10764.
PMID: 39737903
The role of myeloid cells in the pathogenesis of SARS-CoV-2 is well established, in particular as drivers of cytokine production and systemic inflammation characteristic of severe COVID-19. However, the potential...
3.
Seow J, Jefferson G, Keegan M, Yau Y, Snell L, Doores K
PLoS Pathog
. 2024 Nov;
20(11):e1012724.
PMID: 39556615
Over the course of the COVID-19 pandemic, variants have emerged with increased mutations and immune evasive capabilities. This has led to breakthrough infections (BTI) in vaccinated individuals, with a large...
4.
Avanzato V, Bushmaker T, Oguntuyo K, Yinda C, Duyvesteyn H, Stass R, et al.
J Virol
. 2024 Sep;
98(10):e0063824.
PMID: 39240113
Nipah virus (NiV) is a highly pathogenic paramyxovirus capable of causing severe respiratory and neurologic disease in humans. Currently, there are no licensed vaccines or therapeutics against NiV, underscoring the...
5.
Griffith S, Muir L, Suchanek O, Hope J, Pade C, Gibbons J, et al.
bioRxiv
. 2024 Feb;
PMID: 38370662
Immunological determinants favouring emergence of broadly neutralising antibodies are crucial to the development of HIV-1 vaccination strategies. Here, we combined RNAseq and B cell cloning approaches to isolate a broadly...
6.
Doores K
Ann N Y Acad Sci
. 2023 Nov;
1530(1):23-31.
PMID: 37936483
Phleboviruses are zoonotic pathogens found in parts of Africa, Asia, Europe, and North America and cause disease symptoms ranging from self-limiting febrile illness to severe disease, including hemorrhagic diathesis, encephalitis,...
7.
Seow J, Shalim Z, Graham C, Kimuda S, Pillai A, Lechmere T, et al.
mBio
. 2023 Sep;
14(5):e0120623.
PMID: 37747187
With the emergence of SARS-CoV-2 viral variants, there has been an increase in infections in vaccinated individuals. Here, we isolated monoclonal antibodies (mAbs) from individuals experiencing a breakthrough infection (Delta...
8.
Cheetham N, Penfold R, Giunchiglia V, Bowyer V, Sudre C, Canas L, et al.
EClinicalMedicine
. 2023 Sep;
62:102086.
PMID: 37654669
Background: Cognitive impairment has been reported after many types of infection, including SARS-CoV-2. Whether deficits following SARS-CoV-2 improve over time is unclear. Studies to date have focused on hospitalised individuals...
9.
Andreeva D, Gill C, Brockbank A, Hejmej J, Conti-Ramsden F, Doores K, et al.
BJOG
. 2023 Apr;
130(9):1135-1144.
PMID: 37113111
Objective: To determine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence in pregnancy in an inner-city setting and assess associations with demographic factors and vaccination timing. Design: Repeated cross-sectional surveillance...
10.
Calvaresi V, Wrobel A, Toporowska J, Hammerschmid D, Doores K, Bradshaw R, et al.
Nat Commun
. 2023 Mar;
14(1):1421.
PMID: 36918534
SARS-CoV-2 spike glycoprotein mediates receptor binding and subsequent membrane fusion. It exists in a range of conformations, including a closed state unable to bind the ACE2 receptor, and an open...